Who dies from prostate cancer?

[1]  J. Carles,et al.  A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse. , 2014 .

[2]  R. DiPaola,et al.  Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W. Isaacs,et al.  Tracking the clonal origin of lethal prostate cancer. , 2013, The Journal of clinical investigation.

[4]  E. Keller,et al.  Mechanisms of Metastatic Tumor Dormancy , 2013, Journal of clinical medicine.

[5]  L. Holmberg,et al.  Causes of death in men with prostate cancer: an analysis of 50 000 men from the Thames Cancer Registry , 2013, BJU international.

[6]  K. Fizazi,et al.  Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). , 2013 .

[7]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[8]  A. Ravaud,et al.  Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[9]  Jennifer R. Rider,et al.  Temporal trends in cause of death among Swedish and US men with prostate cancer. , 2012, Journal of the National Cancer Institute.

[10]  P. Troncoso,et al.  Cytoreduction and androgen signaling modulation by abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus LHRHa in localized high-risk prostate cancer (PCa): Preliminary results of a randomized preoperative study. , 2012 .

[11]  J. Richie,et al.  Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. , 2012 .

[12]  M. Gleave,et al.  A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer. , 2012 .

[13]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[14]  Arnulf Stenzl,et al.  Circulating and Disseminated Tumor Cells in the Management of Advanced Prostate Cancer , 2011, Advances in urology.

[15]  A. Ravaud,et al.  A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. , 2012, European journal of cancer.

[16]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[17]  K. Hemminki,et al.  What do prostate cancer patients die of? , 2011, The oncologist.

[18]  T. Ragg,et al.  Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Kim-Anh Do,et al.  Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. McKiernan,et al.  Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. , 2007, Urology.

[22]  T. H. van der Kwast,et al.  Tumour features in the control and screening arm of a randomized trial of prostate cancer. , 2006, European urology.

[23]  Jorge Yao,et al.  Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.

[24]  Jaime Pujadas Oláno,et al.  Natural history of early localized prostate cancer. , 2004, JAMA.

[25]  M. Grimm,et al.  Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. , 2002, European urology.

[26]  S. Halford,et al.  Adjuvant mitozantrone chemotherapy in advanced prostate cancer , 2000, BJU international.

[27]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .

[28]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.